Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02108106 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of AG-348 in Healthy Volunteers
A Phase 1 study, sponsored by Agios Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 48
- Enrollment target
NCT02108106 is a Phase 1 study that has completed, run by Agios Pharmaceuticals. The registered enrollment target is 48 participants.
The verdict
NCT02108106, a Phase 1 study, has completed, sponsored by Agios Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of AG-348, and the pharmacodynamic profile of AG-348 with specific biomarkers assessed in the blood.
Interventions
- DRUG Placebo
- DRUG AG-348
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2014-03 |
| Est. Completion | 2014-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02108106
The ClinicalTrials.gov registry entry for NCT02108106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02108106 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02108106 about?
NCT02108106 is a clinical study titled "A Phase I Study of AG-348 in Healthy Volunteers". This is a dose escalation study that will be conducted in healthy volunteers. Multiple cohorts of volunteers will receive ascending oral doses of AG-348 to evaluate the safety and tolerability of a single oral dose of AG-348, the pharmacokinetics (PK) of a single dose of AG-348, and the pharmacodyna...
What is the current status of trial NCT02108106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 48 participants. The study started on 2014-03. Estimated completion is 2014-08.
What interventions are being tested in trial NCT02108106?
The interventions under investigation include: Placebo (DRUG), AG-348 (DRUG).
Who is sponsoring clinical trial NCT02108106?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.